Triapine
- Generic Name
- Triapine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C7H9N5S
- CAS Number
- 143621-35-6
- Unique Ingredient Identifier
- U4XIL4091C
- Background
Triapine has been used in trials studying the treatment of Leukemia, Lung Cancer, Kidney Cancer, Prostate Cancer, and Pancreatic Cancer, among others.
- Associated Conditions
- -
- Associated Therapies
- -
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- Conditions
- Anaplastic Large Cell LymphomaAngioimmunoblastic T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueIntraocular LymphomaNodal Marginal Zone B-cell LymphomaPrimary Central Nervous System Hodgkin LymphomaPrimary Central Nervous System Non-Hodgkin LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell Lymphoma
- Interventions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00293345
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-02-07
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00288093
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2013-01-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 68
- Registration Number
- NCT00095888
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 116
- Registration Number
- NCT00085371
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2004-06-11
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00084877
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
3-Aminopyridine-2-carboxaldehyde Thiosemicarbazone in Treating Patients With Solid Tumors
- Conditions
- First Posted Date
- 2004-05-03
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00004213
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
🇺🇸Arizona Clinical Research Center, Tucson, Arizona, United States
3-AP and Cisplatin in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00081276
- Locations
- 🇺🇸
Gynecologic Oncology Group, Philadelphia, Pennsylvania, United States
3-AP in Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00006218
- Locations
- 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States
3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2013-05-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 36
- Registration Number
- NCT00079014
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 26
- Registration Number
- NCT00078975
- Locations
- 🇨🇦
Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
🇨🇦Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦London Regional Cancer Program at London Health Sciences Centre, London, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.